[ad_1]
Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals Limited have reached an agreement with Pfizer Inc., PF Prism CV and PF Prism IMB BV (Pfizer) for their generic version of Axitinib tablets, 1 mg and 5 mg. Inlyta®1 tablets, 1 mg and 5 mg.
Glenmark announced on November 30, 2020 that it has received tentative approval from the United States Food and Drug Administration (US FDA) for 1 mg and 5 mg generic Axitinib tablets.
According to IQVIATM sales data for the 12-month period ending September 2022, the Inlyta® tablets, 1 mg and 5 mg market2 achieved annual sales of approximately $644.5 million*.
Glenmark’s current portfolio consists of 177 products approved for distribution in the US market and 47 ANDAs approved by the US FDA. In addition to these internal documents,
Glenmark continues to identify and explore external development partnerships to complement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals Ltd. is an innovation-driven global pharmaceutical company specializing in specialty, generic and OTC businesses. It focuses on the main therapeutic areas of respiratory organs, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operates in over 80 countries. Glenmark is among the world’s top 100 biopharmaceutical companies and the world’s top 50 companies in the off-patent sector.
Watch all industry news, banking news and updates on Live Mint. Download Mint News app to get daily market updates.
More Less
[ad_2]
Source link